Against which human papillomavirus types shall we vaccinate and screen? The international perspective

International Journal of Cancer

Volumn 111, Issue 2, 2004, Pages 278-285

  Muñoz, Nubia ^a,f   Xavier Bosch, F ^b   Castellsagué, Xavier ^b   Díaz, Mireia ^b   De Sanjose, Silvia ^b   Hammouda, Doudja ^c   Shah, Keerti V ^d   Meijer, Chris J L M ^e  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE   (Algeria)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

Cervical cancer; Human papillomavirus; Human papillomavirus geographic distribution

Indexed keywords

VACCINE; VIRUS DNA;

ADULT; AFRICA; AFRICA SOUTH OF THE SAHARA; ARTICLE; CANCER SCREENING; CASE CONTROL STUDY; CENTRAL AMERICA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; GEOGRAPHICAL VARIATION (SPECIES); HUMAN; HUMAN PAPILLOMA VIRUS 31; HUMAN PAPILLOMA VIRUS 35; HUMAN PAPILLOMA VIRUS 39; HUMAN PAPILLOMA VIRUS 45; HUMAN PAPILLOMA VIRUS 51; HUMAN PAPILLOMA VIRUS 52; HUMAN PAPILLOMA VIRUS 56; HUMAN PAPILLOMA VIRUS 58; HUMAN PAPILLOMA VIRUS 59; HUMAN PAPILLOMA VIRUS 66; HUMAN PAPILLOMA VIRUS 68; HUMAN PAPILLOMA VIRUS 73; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTH AMERICA; SOUTH ASIA; UTERINE CERVIX CANCER; VACCINATION; VALIDATION PROCESS; VIRUS DETECTION; VIRUS TYPING; WART VIRUS;

AFRICA; CASE-CONTROL STUDIES; DNA, VIRAL; EUROPE; FEMALE; GEOGRAPHY; HEALTH SURVEYS; HUMANS; INTERNATIONAL COOPERATION; MASS SCREENING; NORTH AMERICA; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SOUTH AMERICA; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 3142661757     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20244     Document Type: Article

References (27)

1. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base 5. Lyon: IARC, 2001.
2. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJF, Meijer CJLM, for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;384:518-27.
3. Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
4. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snöders PJF, Peto J, Meijer CJLM, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
5. de Villiers EM. Taxonomic classification of papillomaviruses. Papillomavirus Rep 2001;12:57-63.
6. Bosch FX, Manos M, Muñoz N, Sherman M, Jansen A, Peto J, Schiffman M, Moreno V, Shah KV, IBSCC study group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
7. Muñoz N, Bosch FX, de Sanjosé S, Tafur L, Izarzugaza I, Gili M, Viladiu P, Navarro C, Martos C, Ascunce N, González LC, Kaldor JM, et al. The causal link between human papillormavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992;52:743-9.
8. Eluf-Neto J, Booth M, Muñoz N, Bosch FX, Meijer CJLM, Walboomers JMM. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994;69:114-9.
9. Chaouki N, Bosch FX, Muñoz N, Meijer CJLM, El-Gueddari B, El-Ghazi A, Deacon J, Castellsagué X, Walboomers JMM. The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer 1998;75:546-54.
10. Chichareon S, Herrero R, Muñoz N, Bosch FX, Jacobs MV, Deacon J, Santamaria M, Chongsuvivatwong V, Meijer CJLM, Walboomers JMM. Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst 1998;90:50-7.
11. Ngelangel C, Muñoz N, Bosch FX, Limson GM, Festin MR, Deacon J, Jacobs MV, Santamaria M, Meijer CJLM, Walboomers JMM. Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst 1998;90:43-9.
12. Rolón PA, Smith JS, Muñoz N, Klug SJ, Herrero R, Bosch FX, Llamosas F, Meijer CJLM, Walboomers JMM. Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer 2000;85:486-91.
13. Santos C, Muñoz N, Klug S, Almonte M, Guerrero I, Alvarez M, Velarde C, Galdos O, Castillo M, Walboomers J, Meijer CJLM, Caceres E. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer 2001;85:966-71.
14. Bayo S, Bosch FX, de Sanjose S, Muñoz N, Combita AL, Coursaget P, Diaz M, Dolo A, van Den Brule AJ, Meijer CJLM. Risk factors of invasive cervical cancer in Mali. Int J Epidemiol 2002;31:202-9.
15. Rajkumar T, Franceschi S, Vaccarella S, Gajalakshmi CK, Sharmila A, Snijders PJF, Muñoz N, Meijer CJLM, Herrero R. Role of paan chewing and dietary habits in cervical carcinoma in Chennai, India. Br J Cancer 2003;88:1388-93.
16. Harro CD, Pang YS, Roden RBS, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schilier JT, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:287-92.
17. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
18. th International Multidisciplinary Congress EUROGIN 2003. Final programme and abstracts book. Paris: EUROGIN, 2003.
19. Combita AL, Touze A, Bousarghin L, Christensen ND, Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 2002;76:6480-6.
20. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer 2003;88:63-73.
21. Manos MM, Wright, DK, Lewis, AJ, Broker, TR, Wolinsky, SM. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses In: Furth M, Greaves M, eds. Molecular diagnostics of human cancer. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989. 209-14.
22. de Roda Husman AM, Walboomers JMM, Van den Brule AJC, Meijer CJLM, Snijders PJF. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by polymerase chain reaction. J Gen Virol 1995;76:1057-62.
23. Qu W, Jiang G, Cruz Y, Chang CJ, Ho GYF, Klein RS, Burk RD. PCR detection of human papillormavirus: comparison between MY09/ MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997;35:1304-10.
24. Lo KW, Wong YF, Chan MK, Li JC, Poon JS, Wang VW, Zhu SN, Zhang TM, He ZG, Wu QL, Li GD, Tam JS, et al. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer 2002;100:327-31.
25. Cho NH, An HJ, Jeong JK, Kang S, Kim JW, Kim YT, Park TK. Genotyping of 22 human papillomavirus types by DNA chip in Korean women: comparison with cytologic diagnosis. Am J Obstet Gynecol 2003;188:56-62.
26. Xi LF, Toure P, Critchlow CW, Hawes SE, Dembele B, Sow PS, Kiviat NB. Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. Int J Cancer 2003;103:803-9.
27. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, Scott DR, Sherman ME, Kurman RJ, Glass AG, Anderson SM, Schiffman M. A prospective study of human papillormavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8-15.